Nature Reviews Drug Discovery contents February 2012 Volume 11 Number 2 pp 87-168

Advertisement
Don't wash away your cells! Tecan's new HydroSpeed™ plate washer offers: • extra gentle Cell Protection™ wash settings • high cell recovery using tuneable aspiration settings • Anti-Clogging™ function for reliable ELISA washing Learn more
TABLE OF CONTENTS
February 2012 Volume 11 Number 2		Advertisement
Impact Factor 28.712 *	In this issue Comment News and Analysis Research Highlights Reviews Correspondence Also this month  Featured article: Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy Mark J. Millan et al.	The Combination Approaches for Cancer Therapies meeting will bring together senior level representatives from pharma and biotech to explore how this new synergistic approach is shaping drug development and patient care in the clinic. This is the world's only commercially focused event to accelerate progress in the development of combinatorial approaches. Register Now Download the brochure
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Don't miss out on $3 million in research funding Seeking immediate proposals for projects focused on modulation of: •B cells •Glial cells, including microglia, macrophages, astrocytes •CNS ion channels, exchangers, transporters Apply TODAY at www.FastForward.org Deadline 05/01/12
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Chemical Biology Free Poster on Human protein methyltransferases Nature Chemical Biology presents a poster highlighting the human protein methyltransferase families, the small molecules known to target them and the prospects for PMT-focused drug development. Download the Poster today by visiting: www.nature.com/nchembio/poster/hpm Poster sponsored by:
In this issue p87 | doi:10.1038/nrd3658 Full Text
Comment: (Mis)treating the pharmacogenetic incidentalome Isaac S. Kohane p89 | doi:10.1038/nrd3659 Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
2011 FDA drug approvals Asher Mullard p91 | doi:10.1038/nrd3657 The US FDA approved 30 new therapeutics last year, including 11 first-in-class agents. PDF
NEWS IN BRIEF Globalization of clinical trials plateaus? | The NCATS that got the cream | Introducing lead-oriented synthesis p95 | doi:10.1038/nrd3666 PDF
BIOBUSINESS BRIEFS Deal watch: Abbott boosts investment in NRF2 activators for reducing oxidative stress Sarah Crunkhorn p96 | doi:10.1038/nrd3655 PDF
BIOBUSINESS BRIEFS Trial watch: BTK inhibitor shows positive results in B cell malignancies Charlotte Harrison p96 | doi:10.1038/nrd3656 PDF
PATENT WATCH Regeneron and Genentech's VEGF trap dispute settles... and continues | Patent extensions for combination therapies | WIPO launches patent licensing feature | Inhibitor of apoptosis proteins Charlotte Harrison p98 | doi:10.1038/nrd3667 PDF
AN AUDIENCE WITH RuiPing Dong p100 | doi:10.1038/nrd3668 RuiPing Dong, head of emerging markets R&D at Merck & Co., discusses the strategy behind the firm's recent US$1.5 billion expansion into China. PDF
FROM THE ANALYST'S COUCH The neuropathic pain market Sarah Nightingale p101 | doi:10.1038/nrd3624 This article discusses the drug pipeline for neuropathic pain, for which the market is forecast to grow by 50% by 2020. PDF
FRESH FROM THE PIPELINE Ruxolitinib Ruben A. Mesa, Uma Yasothan & Peter Kirkpatrick p103 | doi:10.1038/nrd3652 Janus kinase inhibitor approved by the US Food and Drug Administration for the treatment of myelofibrosis. PDF
RESEARCH HIGHLIGHTS Top Protein conformational diseases: Rescuing protein homeostasis p105 | doi:10.1038/nrd3662 PDF Obesity and diabetes: An FGFR antibody with long-lasting effects p106 | doi:10.1038/nrd3660 PDF Drug delivery: Encapsulation improves therapeutic stem cell action p106 | doi:10.1038/nrd3661 PDF Medicinal Chemistry: Shades of chemical beauty p107 | doi:10.1038/nrd3663 PDF Anticancer drugs: Keeping one step ahead p108 | doi:10.1038/nrd3664 PDF IN BRIEF Lung disease: Blocking TGFß improves emphysema | Drug safety: Predicting adverse drug reactions | Neurodegenerative disorders: A neuroprotective role for sirtuin 1 PDF Drug Discovery JOBS of the week Stem Cells for Drug Discovery and Neural Repair UC Davis MRes in Drug Discovery and Development Imperial College London Scientist / Senior Scientist Development Toxicology Genentech Research Investigator in Cancer Biology BeiGene Inc. Research Assistant - Student Worker Kelly Scientific Resources More Science jobs from Drug Discovery EVENT Advances and Progress in Drug Design 21.-22.02.12 London, UK More science events from
REVIEWS		Top
Targeting IAP proteins for therapeutic intervention in cancer Simone Fulda & Domagoj Vucic p109 | doi:10.1038/nrd3627 Inhibitor of apoptosis (IAP) antagonists have recently entered the stage of clinical evaluation for many different types of cancer. Here, Fulda and Vucic review the different approaches that have been used to target IAP proteins, and discuss their translation into therapeutic anticancer strategies. Abstract | Full Text | PDF | Supplementary information
RNA therapeutics: beyond RNA interference and antisense oligonucleotides Ryszard Kole, Adrian R. Krainer & Sidney Altman p125 | doi:10.1038/nrd3625 Here, the authors highlight how RNA-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression, and so may be useful for treating disorders such as Duchenne muscular dystrophy, spinal muscular atrophy and ß-thalassaemia. Abstract | Full Text | PDF
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy Mark J. Millan, Yves Agid, Martin Brüne, Edward T. Bullmore, Cameron S. Carter, Nicola S. Clayton, Richard Connor, Sabrina Davis, Bill Deakin, Robert J. DeRubeis, Bruno Dubois, Mark A. Geyer, Guy M. Goodwin, Philip Gorwood, Thérèse M. Jay, Marian Joëls, Isabelle M. Mansuy, Andreas Meyer-Lindenberg, Declan Murphy, Edmund Rolls, Bernd Saletu, Michael Spedding, John Sweeney, Miles Whittington & Larry J. Young p141 | doi:10.1038/nrd3628 Studies of psychiatric disorders have traditionally focused on emotional symptoms, such as depression, anxiety and hallucinations, but poorly controlled cognitive deficits are also prominent and severely compromise quality of life. This article critically discusses our understanding of the nature and causes of cognitive impairment in psychiatric disorders, and reviews the opportunities and challenges in improving cognition in patients, including the development of more effective translational research approaches. Abstract | Full Text | PDF | Supplementary information
CORRESPONDENCE		Top
Correspondence: The critical impact of time discounting on economic incentives to overcome the antibiotic market failure Brad Spellberg, Priya Sharma & John H. Rex p168 | doi:10.1038/nrd3560-c1 Full Text | PDF | Supplementary information
Corrigendum: Quarter-century quest for malaria vaccine shows signs of success Alisa Opar p168 | doi:10.1038/nrd3650 Full Text | PDF
Erratum: Designing antimicrobial peptides: form follows function Christopher D. Fjell, Jan A. Hiss, Robert E. W. Hancock & Gisbert Schneider p168 | doi:10.1038/nrd3653 Full Text | PDF
Advertisement
Nature Reviews Cancer POSTER - Proteasome inhibition and cancer therapy Author: Q. Ping Dou This poster highlights recent achievements and progress in targeting the ubiquitin-proteasome degradation pathway for cancer therapy. Access the Poster FREE online! www.nature.com/nrc/posters/proteasome This Poster is freely available thanks to sponsorship from Onyx Pharmaceuticals, Inc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.